TransMedics Group, Inc. (TMDX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 98.28M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 104.14M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 54.14M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $98.28M | (m) | (m) | $104.14M | $54.14M | (m) |
| 2026-03-31 | (m) | $91.92M | (m) | (m) | $90.73M | $49.89M | (m) |
| 2025-12-31 | (m) | $89.31M | (m) | (m) | $84.28M | $48.88M | (m) |
| 2025-09-30 | (m) | $79.72M | (m) | (m) | $80.70M | $44.51M | (m) |
| 2025-06-30 | (m) | $56.62M | (m) | (m) | $104.85M | $38.87M | (m) |
| 2025-03-31 | (m) | $55.60M | (m) | (m) | $142.03M | $43.38M | (m) |
| 2024-12-31 | (m) | $59.91M | (m) | (m) | $97.72M | $46.55M | (m) |
| 2024-09-30 | (m) | $60.05M | $330.09M | (m) | $90.13M | $52.15M | (m) |
| 2024-06-30 | (m) | $54.33M | $362.75M | (m) | $81.16M | $48.67M | (m) |
| 2024-03-31 | (m) | $50.22M | $350.22M | (m) | $81.94M | $48.54M | (m) |
| 2023-12-31 | (m) | $54.93M | $394.81M | (m) | $63.58M | $44.23M | (m) |
| 2023-09-30 | (m) | $49.10M | $427.11M | (m) | $60.65M | $39.37M | (m) |
| 2023-06-30 | (m) | $32.02M | $582.21M | (m) | $47.52M | $30.55M | (m) |
| 2023-03-31 | (m) | $28.64M | $195.38M | (m) | $38.62M | $23.96M | (m) |
| 2022-12-31 | (m) | $23.66M | $201.18M | (m) | $27.61M | $20.61M | (m) |
| 2022-09-30 | (m) | $20.69M | $204.46M | (m) | $22.04M | $18.57M | (m) |
| 2022-06-30 | $71.06M | $22.74M | $30.39M | $27.70M | $12.98M | $17.47M | 3.12× |
| 2022-03-31 | $83.72M | $20.26M | $17.90M | $54.10M | $11.72M | $16.71M | 4.13× |
| 2021-12-31 | $98.39M | $23.24M | $25.58M | $66.87M | $5.93M | $14.86M | 4.23× |
| 2021-09-30 | $107.00M | $15.92M | $22.50M | $80.36M | $4.15M | $14.87M | 6.72× |
| 2021-06-30 | $118.52M | $15.08M | $25.31M | $86.94M | $6.27M | $13.01M | 7.86× |
| 2021-03-31 | $125.51M | $11.76M | $26.73M | $91.39M | $7.39M | $11.82M | 10.68× |
| 2020-12-31 | $132.51M | $11.88M | $24.58M | $101.06M | $6.86M | $11.93M | 11.15× |
| 2020-09-30 | $138.85M | $13.62M | $21.40M | $111.32M | $6.14M | $12.98M | 10.19× |
| 2020-06-30 | $143.81M | $13.82M | $51.15M | $88.22M | $4.43M | $12.55M | 10.41× |
| 2020-03-31 | $78.69M | $15.04M | $24.74M | $47.82M | $6.13M | $11.36M | 5.23× |
| 2019-12-28 | $87.25M | $16.11M | $20.09M | $60.60M | $6.56M | $11.22M | 5.41× |
| 2019-09-28 | $94.74M | $14.64M | $20.41M | $67.86M | $6.46M | $10.54M | 6.47× |
| 2019-06-29 | $103.34M | $15.38M | $47.24M | $48.99M | $7.11M | $11.22M | 6.72× |
| 2019-03-30 | (m) | $16.20M | $12.21M | (m) | $5.15M | $11.29M | (m) |
| 2018-12-29 | (m) | $12.55M | $20.24M | (m) | $3.44M | $9.28M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |